Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia

Haematologica

Volumn 87, Issue 3, 2002, Pages 257-263

  Bassan, Renato ^a   Lerede, Teresa ^a   Borleri, Gianmaria ^a   Chiodini, Barbara ^a   Rossi, Andrea ^a   Buelli, Maurizio ^a   Rambaldi, Alessandro ^a   Viero, Piera ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Cyclosporin; Idarubicin; Multidrug resistance; Refractory acute leukemia

Indexed keywords

CHLORPHENIRAMINE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; IDARUBICIN; LORAZEPAM; MULTIDRUG RESISTANCE PROTEIN; RECOMBINANT COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MULTIDRUG RESISTANCE; PHASE 1 CLINICAL TRIAL; PROGNOSIS; PROTEIN EXPRESSION;

ACUTE DISEASE; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINE; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0036197486     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy
2. Treatment of refractory AML
3. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
4. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
5. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia
6. Correlation of multidrug resistance (MDR1) protein expression, with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases
7. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients
8. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
9. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study
10. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group pilot study
11. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
12. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporine A and cremophor EL
13. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
14. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420
15. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia
16. Selected pharmacologic characteristics of idarubicin and idarubicinol
17. Idarubicin v daunorubicin: Preclinical and clinical pharmacokinetic studies
18. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
19. Susceptibility of idarubicin, daunorubicin, and their alcohol metabolites to transport-mediated multidrug resistance
20. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy
21. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia
22. Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance
23. + human leukemic cells
24. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute acute myeloid leukemia
25. Randomized comparison of sequential high-dose cytosine arabinoside and idarubicin (s-HAI) with or without chemo-modulation by fludarabine in refractory and relapsed acute myeloid leukemia
26. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia
27. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myetoid leukemia?
28. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
29. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study 4